<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836520</url>
  </required_header>
  <id_info>
    <org_study_id>BC-NEO-IIT-SHR6390</org_study_id>
    <nct_id>NCT04836520</nct_id>
  </id_info>
  <brief_title>SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.</brief_title>
  <official_title>Single-arm, Single-center, PhaseⅡ Clinical Study of SHR6390 Combined With Anastrozole for Preoperative Treatment of Hormone Receptor Positive and HER2 Negative Early or Locally Advanced Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to assess effect of SHR6390 combined with anastrozole on&#xD;
      proliferation of HR-positive HER2-negative breast cancer tumor cells before surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, single-center, open-label Phase II clinical study. The purpose of this&#xD;
      study was to evaluate the effect of SHR6390 combined with anastrozole on the proliferative&#xD;
      activity of HR-positive HER2-negative breast cancer tumor cells before surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Ki67 scores</measure>
    <time_frame>up to 5 months</time_frame>
    <description>Serial measures of Ki67 (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RCB (0-1) after surgery</measure>
    <time_frame>5 months</time_frame>
    <description>Rate of Residual Cancer Burden 0-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) evaluated by the investigator</measure>
    <time_frame>16 weeks</time_frame>
    <description>ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tpCR</measure>
    <time_frame>5 months</time_frame>
    <description>pCR is defined as the absence of noninvasive tumor residuals in breast and axillary lymph nodes (ypT0/is ypN0) after neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed using NCI Common Terminology Criteria for Adverse Events v5.0 (CTCAE)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SHR6390+anatrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hormone receptor positive, HER2 negative participants will receive SHR6390 in combination with anatrozole before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR6390+anatrozole</intervention_name>
    <description>SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.</description>
    <arm_group_label>SHR6390+anatrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.Female subjects aged 18 to 75 years old, meet any of the following:&#xD;
&#xD;
          1. Both ovaries have been removed, or the age is ≥60 years old;&#xD;
&#xD;
          2. Age &lt;60 years, natural post-menopausal state (defined as spontaneous menstrual&#xD;
             cessation for at least 12 consecutive months without other pathological or&#xD;
             physiological reasons), E2 and FSH are at postmenopausal levels;&#xD;
&#xD;
          3. Premenopausal or perimenopausal female subjects must be willing to receive LHRH&#xD;
             agonist treatment during the study; 2.T2-T4cN0M0 invasive breast cancer (according to&#xD;
             the AJCC 8th edition breast cancer clinical staging guidelines), the tumor must be&#xD;
             surgically resectable, the measurable lesion conforms to the RECIST 1.1 standard, and&#xD;
             the maximum diameter of the primary tumor has been evaluated by clinical or imaging&#xD;
             evaluation ≥ 2cm; 3.Willing to accept biopsy; 4.Luminal A confirmed by&#xD;
             immunohistochemistry, ER≥50% and PR≥50%; 5.HER2 negative, defined as&#xD;
             immunohistochemical test 0/1+; or FISH test HER2/CEP17 ratio is less than 2.0 or HER2&#xD;
             gene copy number is less than 4; 6.Patients are suitable for neoadjuvant therapy and&#xD;
             willing to accept (judged by the investigator); 7.ECOG performance status score 0 or&#xD;
             1; 8.The expected survival period is not less than 12 weeks; 9.Adequate function of&#xD;
             major organs； 10.Voluntary participation in the study, signed informed consent, good&#xD;
             compliance and willingness to cooperate with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastases confirmed by imaging or pathology, not including lymph node metastases in&#xD;
             the ipsilateral and/or contralateral thoracic region or mediastinum;&#xD;
&#xD;
          2. Inflammatory breast cancer, bilateral breast cancer or DCIS, invasive breast cancer&#xD;
             with multiple focal lesions;&#xD;
&#xD;
          3. Previous pathological diagnosis of HER2-positive breast cancer;&#xD;
&#xD;
          4. Suffering from gastrointestinal diseases such as intestinal obstruction, peptic ulcer&#xD;
             or active bleeding, which affects the taking and absorption of drugs;&#xD;
&#xD;
          5. Previously treated with radiotherapy, chemotherapy, surgery (not including&#xD;
             percutaneous puncture) or molecular targeted treatment;&#xD;
&#xD;
          6. Previously received any CDK4/6 inhibitor drug treatment;&#xD;
&#xD;
          7. Participation in any other clinical trials within 4 weeks of enrollment；&#xD;
&#xD;
          8. Concurrent use of any other Anti-cancer drugs；&#xD;
&#xD;
          9. Other malignancies within 5 years, except cured in-situ of uterine cervix carcinoma ,&#xD;
             skin basal cell carcinoma and squamous-cell carcinoma;&#xD;
&#xD;
         10. History of heart disease: (1) Arrhythmias requiring medical treatment or clinical&#xD;
             significance, (2) Myocardial infarction, (3) Heart failure, (4)Any heart diseases that&#xD;
             investigator believes not suitable for this study;&#xD;
&#xD;
         11. History of allergy or hypersensitivity to any of the study drugs or study drug&#xD;
             components; history of immunodeficiency including HIV-positive, active hepatitis B/C,&#xD;
             other acquired, congenital immunodeficiency disease or history of organ&#xD;
             transplantation；&#xD;
&#xD;
         12. A clear history of neurological or mental disorders, including epilepsy or dementia；&#xD;
&#xD;
         13. Pregnant or breastfeeding women. Women of childbearing potential who have a positive&#xD;
             pregnancy test or unwilling to use adequate contraception prior to enrollment and for&#xD;
             the duration of study participation；&#xD;
&#xD;
         14. According to the investigator's judgment, there is a concomitant disease that&#xD;
             seriously endangers the safety of subjects or affects the completion of the study&#xD;
             (including but not limited to severe hypertension, severe diabetes, active infection,&#xD;
             thyroid disease that cannot be controlled by drugs)；&#xD;
&#xD;
         15. Any condition which in the investigator's opinion makes the subjects unsuitable for&#xD;
             the study participation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liu Hong, M.D.</last_name>
    <phone>022-23340123</phone>
    <email>lh713@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TianJin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong MD Liu, professor</last_name>
      <phone>18622221169</phone>
      <email>lh713@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

